Alpha-1 Antitrypsin Deficiency (A1AD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alpha 1 Antitrypsin Deficiency Pipeline Drugs Market Report Overview
Alpha-1 Antitrypsin Deficiency (A1AD) pipeline market research report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects.
Key targets | Alpha 1 Antitrypsin, Neutrophil Elastase, Lactate Dehydrogenase, and Plasminogen Activator Inhibitor 1 |
Key MoA | Alpha 1 Antitrypsin Activator, Alpha 1 Antitrypsin Replacement, Alpha 1 Antitrypsin Inhibitor, Neutrophil Elastase Inhibitor, Lactate Dehydrogenase Inhibitor, and Plasminogen Activator Inhibitor 1 Activator |
Key RoA | Inhalational, Subcutaneous, Oral, Intravenous, Intramuscular, and Parenteral |
Key molecule type | Gene Therapy, Small Molecule, Blood Derivative, Antisense RNAi Oligonucleotide, Oligonucleotide, Cell Therapy, Recombinant Protein, Fusion Protein, and Synthetic Peptide |
Key companies | Kamada Pharmaceuticals, Intellia Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Centessa Pharmaceuticals Plc, Grifols SA, Novo Nordisk AS, pH Pharma Co Ltd, Vertex Pharmaceuticals Inc, and ADARx Pharmaceuticals Inc |
Key Targets in the A1AD Pipeline Market
The key targets in the Alpha 1 Antitrypsin Deficiency Pipeline Drugs Market are Alpha 1 Antitrypsin, Neutrophil Elastase, Lactate Dehydrogenase, and Plasminogen Activator Inhibitor 1. Alpha 1 Antitrypsin has the highest pipeline products.
A1AD Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the A1AD Pipeline Market
The key MoA in the A1AD pipeline market are Alpha 1 Antitrypsin Activator, Alpha 1 Antitrypsin Replacement, Alpha 1 Antitrypsin Inhibitor, Neutrophil Elastase Inhibitor, Lactate Dehydrogenase Inhibitor, and Plasminogen Activator Inhibitor 1 Activator. Alpha 1 Antitrypsin Activator has the highest pipeline products.
A1AD Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the A1AD Pipeline Market
The key RoA in the A1AD pipeline market are inhalational, subcutaneous, oral, intravenous, intramuscular, and parenteral. Inhalational has the highest number of pipeline products.
A1AD Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the A1AD Pipeline Market
The key molecule types in the A1AD pipeline market are Gene Therapy, Small Molecule, Blood Derivative, Antisense RNAi Oligonucleotide, Oligonucleotide, Cell Therapy, Recombinant Protein, Fusion Protein, and Synthetic Peptide. Small molecule has the highest number of pipeline products.
A1AD Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the A1AD Pipeline Market
The key companies in the A1AD pipeline market are Kamada Pharmaceuticals, Intellia Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Centessa Pharmaceuticals Plc, Grifols SA, Novo Nordisk AS, pH Pharma Co Ltd, Vertex Pharmaceuticals Inc, and ADARx Pharmaceuticals Inc. Kamada Pharmaceuticals has the highest pipeline products.
Arrowhead Pharmaceuticals Inc: Arrowhead Pharmaceuticals Inc (Arrowhead), formerly known as Arrowhead Research Corp, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis, and renal cell carcinoma. It also offers the design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
A1AD Pipeline Market, by Companies
To know more about companies, download a free report sample
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Alnylam Pharmaceuticals Inc
Apic Bio Inc
Applied Genetic Technologies Corp
Arrowhead Pharmaceuticals Inc
Beam Therapeutics Inc
BioMarin Pharmaceutical Inc
Caravella Biopharma SA
Centessa Pharmaceuticals Plc
Editas Medicine Inc
Evolve Biologics Inc
Graphite Bio Inc
Grifols SA
Hepatx Corp
Inhibrx Inc
Intellia Therapeutics Inc
International Stem Cell Corp
Kamada Pharmaceuticals
Korro Bio Inc
Krystal Biotech Inc
LEXEO Therapeutics LLC
Liminal BioSciences Inc
Logicbio Therapeutics Inc
Mereo Biopharma Group Plc
Moderna Inc
Novo Nordisk AS
pH Pharma Co Ltd
PlantForm Corp
Promethera Biosciences SA
Renovion Inc
Santhera Pharmaceuticals Holding AG
Shape Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Vera Therapeutics Inc
Vertex Pharmaceuticals Inc
Wave Life Sciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the A1AD Pipeline market?
The key targets in the A1AD pipeline market are Alpha 1 Antitrypsin, Neutrophil Elastase, Lactate Dehydrogenase, and Plasminogen Activator Inhibitor 1.
-
What are the key MoA in the A1AD pipeline market?
The key MoA in the A1AD pipeline market are Alpha 1 Antitrypsin Activator, Alpha 1 Antitrypsin Replacement, Alpha 1 Antitrypsin Inhibitor, Neutrophil Elastase Inhibitor, Lactate Dehydrogenase Inhibitor, and Plasminogen Activator Inhibitor 1 Activator.
-
What are the key RoA in the A1AD pipeline market?
The key RoA in the A1AD pipeline market are inhalational, subcutaneous, oral, intravenous, intramuscular, and parenteral.
-
What are the key molecule types in the A1AD pipeline market?
The key molecule types in the A1AD pipeline market are Gene Therapy, Small Molecule, Blood Derivative, Antisense RNAi Oligonucleotide, Oligonucleotide, Cell Therapy, Recombinant Protein, Fusion Protein, and Synthetic Peptide.
-
What are the key companies in the A1AD pipeline market?
The key companies in the A1AD pipeline market are Kamada Pharmaceuticals, Intellia Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Centessa Pharmaceuticals Plc, Grifols SA, Novo Nordisk AS, pH Pharma Co Ltd, Vertex Pharmaceuticals Inc, and ADARx Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.